Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today that members of its management ...

French TechBio startup Cure51 and 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced ...

PARIS, Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc., a leader in single cell and spatial biology, announced today that Cure51 will deploy 10x Genomics ...

Cure51 plans to analyze more than 1,000 tumor samples from exceptional cancer survivors PARIS, Oct. 31, 2024 /PRNewswire/ -- French TechBio startup Cure51 and 10x Genomics, Inc., a leader in ...

Dissociated sorted cells were assessed for concentration and viability via Luna-FL cell counter (Logos Biosystems). Cells deemed to be at least 90% viable were loaded on a Chromium Single Cell ...

Axxcess Wealth Management LLC boosted its holdings in shares of 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 38.5% during ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 17.28% ...

X Genomics ( (TXG) ) has realeased its Q3 earnings. Here is a breakdown of the information 10X Genomics presented to its investors. 10x ...

Analyst Daniel Brennan of TD Cowen maintained a Hold rating on 10x Genomics (TXG – Research Report), retaining the price target of $18.00. Daniel Brennan has given his Hold rating due to a ...

PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Tuesday reported a loss of $35.8 million in its third quarter. On a per-share basis, the Pleasanton, California-based ...